RU99119493A - MEANS USED IN THE TREATMENT OF TUMOR LYMPHATIC TISSUE - Google Patents

MEANS USED IN THE TREATMENT OF TUMOR LYMPHATIC TISSUE

Info

Publication number
RU99119493A
RU99119493A RU99119493/14A RU99119493A RU99119493A RU 99119493 A RU99119493 A RU 99119493A RU 99119493/14 A RU99119493/14 A RU 99119493/14A RU 99119493 A RU99119493 A RU 99119493A RU 99119493 A RU99119493 A RU 99119493A
Authority
RU
Russia
Prior art keywords
antibody
drug according
activity
cytotoxic activity
tumor
Prior art date
Application number
RU99119493/14A
Other languages
Russian (ru)
Other versions
RU2177805C2 (en
Inventor
Ясуо КОИСИХАРА
Ясуси ЕСИМУРА
Original Assignee
Чугаи Сейяку Кабусики Кайся
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чугаи Сейяку Кабусики Кайся filed Critical Чугаи Сейяку Кабусики Кайся
Publication of RU99119493A publication Critical patent/RU99119493A/en
Application granted granted Critical
Publication of RU2177805C2 publication Critical patent/RU2177805C2/en

Links

Claims (1)

1. Лекарственное средство, применяемое при лечении опухолей лимфатической ткани (за исключением миеломы), включающее в качестве активного ингредиента антитело, которое специфически связывается с белком, имеющим аминокислотную последовательность, указанную в SEQ ID NO: 1, и которое обладает цитотоксической активностью.1. Drug used in the treatment of tumors of lymphatic tissue (except myeloma), comprising as an active ingredient an antibody that specifically binds to a protein having the amino acid sequence indicated in SEQ ID NO: 1, and which has cytotoxic activity. 2. Лекарственное средство по п.1, отличающееся тем, что указанная опухоль лимфатической ткани представляет собой опухоль Т-клеток. 2. The drug according to claim 1, characterized in that said tumor of the lymphatic tissue is a tumor of T cells. 3. Лекарственное средство по п.1, отличающееся тем, что указанная опухоль лимфатической ткани представляет собой опухоль В-клеток (за исключением миеломы). 3. The drug according to claim 1, characterized in that said tumor of the lymphatic tissue is a tumor of B cells (with the exception of myeloma). 4. Лекарственное средство по п.1, отличающееся тем, что указанное антитело представляет собой моноклональное антитело. 4. The drug according to claim 1, characterized in that said antibody is a monoclonal antibody. 5. Лекарственное средство по п.1, отличающееся тем, что указанная цитотоксическая активность представляет собой антитело-обусловленную клеточнозависимую цитотоксичность (ADCC/АОКЦ активность). 5. The drug according to claim 1, characterized in that said cytotoxic activity is an antibody-mediated cell-dependent cytotoxicity (ADCC / AOCC activity). 6. Лекарственное средство по п.1, отличающееся тем, что указанная цитотоксическая активность представляет собой комплементзависимую цитотоксичность (CDC/КЗЦ активность). 6. The drug according to claim 1, characterized in that said cytotoxic activity is complement-dependent cytotoxicity (CDC / CSC activity). 7. Лекарственное средство по п.4, отличающееся тем, что указанное антитело содержит константную область Cγ из человеческого антитела. 7. The drug according to claim 4, characterized in that said antibody contains a constant region of Cγ from a human antibody. 8. Лекарственное средство по п.7, отличающееся тем, что указанная константная область Cγ из человеческого антитела представляет собой Cγ1 или Cγ3.
9. Лекарственное средство по п.4, отличающееся тем, что указанное антитело представляет собой антитело против НМ1.24.8. The drug according to claim 7, characterized in that said constant region Cγ from a human antibody is Cγ1 or Cγ3.
9. The drug according to claim 4, characterized in that said antibody is an anti-HM1.24 antibody. 10. Лекарственное средство по п.4, отличающееся тем, что указанное антитело представляет собой химерное антитело или гуманизированное антитело. 10. The drug according to claim 4, characterized in that said antibody is a chimeric antibody or a humanized antibody. 11. Лекарственное средство по п.9, отличающееся тем, что указанное антитело представляет собой химерное атитело против НМ1.24. 11. The drug according to claim 9, characterized in that said antibody is a chimeric anti-HM1.24 antibody. 12. Лекарственное средство по п.9, отличающееся тем, что указанное антитело представляет собой гуманизированное антитело против НМ1.24. 12. Drug according to claim 9, characterized in that said antibody is a humanized anti-HM1.24 antibody. 13. Лекарственное средство по п.1, отличающееся тем, что указанное антитело специфически связывается с эпитопом, распознаваемым антителом против НМ1.24. 13. The drug according to claim 1, characterized in that said antibody specifically binds to the epitope recognized by the anti-HM1.24 antibody. 14. Антитело, которое специфически связывается с белком, имеющим аминокислотную последовательность, указанную в SEQ ID NO:1, и которое обладает цитотоксической активностью. 14. An antibody that specifically binds to a protein having the amino acid sequence shown in SEQ ID NO: 1, and which has cytotoxic activity. 15. Антитело по п.14, отличающееся тем, что указанная цитотоксическая активность представляет собой антитело-обусловленную клеточно-зависимую цитотоксичность (ADCC/АОКЦ активность). 15. The antibody according to claim 14, wherein said cytotoxic activity is antibody-mediated cell-dependent cytotoxicity (ADCC / AOCC activity). 16. Антитело по п.14, отличающееся тем, что указанная цитотоксическая активность представляет собой комплемент-зависимую цитотоксичность (CDC/КЗЦ активность). 16. The antibody according to 14, characterized in that said cytotoxic activity is a complement-dependent cytotoxicity (CDC / CSC activity).
RU99119493/14A 1997-02-12 1998-02-12 Agent used in treatment of lymphatic tissue tumors RU2177805C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4141097 1997-02-12
JP9/41410 1997-02-12

Publications (2)

Publication Number Publication Date
RU99119493A true RU99119493A (en) 2001-06-27
RU2177805C2 RU2177805C2 (en) 2002-01-10

Family

ID=12607597

Family Applications (1)

Application Number Title Priority Date Filing Date
RU99119493/14A RU2177805C2 (en) 1997-02-12 1998-02-12 Agent used in treatment of lymphatic tissue tumors

Country Status (20)

Country Link
US (2) US6503510B2 (en)
EP (1) EP0997152B1 (en)
KR (2) KR100655979B1 (en)
CN (1) CN1191855C (en)
AT (1) ATE297219T1 (en)
AU (1) AU724133B2 (en)
BR (1) BR9811094A (en)
CA (1) CA2280875C (en)
DE (1) DE69830492T2 (en)
ES (1) ES2241114T3 (en)
HK (1) HK1026368A1 (en)
HU (1) HUP0001136A3 (en)
IL (1) IL131381A0 (en)
NO (1) NO993866L (en)
PL (1) PL190065B1 (en)
RU (1) RU2177805C2 (en)
SK (1) SK110099A3 (en)
TR (1) TR199901949T2 (en)
UA (1) UA65561C2 (en)
WO (1) WO1998035698A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW442493B (en) * 1993-10-15 2001-06-23 Toshio Hirano A membrane protein polypeptide having pre-B cell growth-supporting ability and a gene thereof
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
DE69942215D1 (en) * 1998-02-25 2010-05-12 Chugai Pharmaceutical Co Ltd Method for immunochemical testing of the anti-HM1.24 antibody
ES2307526T3 (en) 1999-08-23 2008-12-01 Chugai Seiyaku Kabushiki Kaisha POTENTIALS OF THE EXPRESSION OF THE ANTIGEN HM1.24.
ATE457318T1 (en) * 2000-12-28 2010-02-15 Kyowa Hakko Kirin Co Ltd MONOCLONAL ANTIBOD DIRECTED AGAINST THE HUMAN BST2 ANTIGEN
JP3986439B2 (en) * 2001-02-07 2007-10-03 中外製薬株式会社 Hematopoietic tumor therapeutic agent
US7332289B2 (en) 2001-03-09 2008-02-19 Chugai Seiyaku Kabushiki Kaisha Method of purifying protein
US7888478B2 (en) 2002-09-11 2011-02-15 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20050226869A1 (en) * 2001-10-19 2005-10-13 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US7858330B2 (en) 2001-10-19 2010-12-28 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
EP3192528A1 (en) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
US20030223998A1 (en) * 2002-02-27 2003-12-04 Lamb Lawrence S. Targeted immunotherapy of acute lymphoblastic leukemia (ALL)
US20080219974A1 (en) * 2002-03-01 2008-09-11 Bernett Matthew J Optimized antibodies that target hm1.24
EP1666501A4 (en) * 2003-08-11 2008-12-24 Chugai Pharmaceutical Co Ltd Sugar chain-modified anti-hm1.24 antibody
WO2005034994A1 (en) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Remedy for solid tumor
WO2006046751A1 (en) * 2004-10-26 2006-05-04 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody having modified sugar chain
US20080299128A1 (en) * 2006-06-20 2008-12-04 Myung Kim Effect of Bst2 on inflammation
US8329186B2 (en) 2004-12-20 2012-12-11 Isu Abxis Co., Ltd Treatment of inflammation using BST2 inhibitor
WO2008036688A2 (en) 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
BRPI0817427A8 (en) 2007-10-16 2019-01-29 Chugai Pharmaceutical Co Ltd anti-bst2 antibody
TWI516501B (en) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9 antagonists
US9123149B2 (en) * 2013-03-15 2015-09-01 Columbia Insurance Company Expert color system for color selection with color harmony and color emotion intelligence
CN107619443B (en) * 2016-07-14 2020-08-14 深圳宾德生物技术有限公司 Monoclonal antibody against human and mouse CD317 and preparation method and application thereof
CN109748964B (en) * 2017-11-01 2020-11-17 深圳宾德生物技术有限公司 CD317 single-chain antibody 317scFv, coding sequence thereof, preparation method and application

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
WO1992019759A1 (en) 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
TW442493B (en) * 1993-10-15 2001-06-23 Toshio Hirano A membrane protein polypeptide having pre-B cell growth-supporting ability and a gene thereof
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
EP0972524A4 (en) * 1997-02-28 2001-03-28 Chugai Pharmaceutical Co Ltd Lymphocyte activation inhibitors
CA2305712A1 (en) * 1997-10-03 1999-04-15 Chugai Seiyaku Kabushiki Kaisha Natural humanized antibody
KR100362974B1 (en) * 1997-10-14 2002-11-30 츄가이 세이야꾸 가부시키가이샤 Potentiator for antibody against lymphoid tumor

Similar Documents

Publication Publication Date Title
RU99119493A (en) MEANS USED IN THE TREATMENT OF TUMOR LYMPHATIC TISSUE
Riechmann et al. Reshaping human antibodies for therapy
KR102089114B1 (en) Antigen binding protein and its use as addressing product for the treatment of cancer
EP1805222B1 (en) Antibodies directed to the mammalian eag1 ion channel protein
US7381803B1 (en) Humanized antibodies against CD3
AU2017207947B2 (en) PSMA binding antibody and uses thereof
JP5906233B2 (en) Anti-ErbB3 antibody
RU2626527C1 (en) Therapeutic canine immunoglobulins and methods for their use
KR101683884B1 (en) Anti-epcam antibody and uses thereof
CN103732621B (en) Anti-nerve growth factor antibodies and methods of making and using same
US11319378B2 (en) Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
RU99109034A (en) RECONSTRUCTED HUMAN ANTI-HM 1.24 ANTIBODY
KR20160007478A (en) Human igg1 fc region variants and uses thereof
RU2011110405A (en) AGENTS BINDING THE FRIZZLED RECEPTOR AND THEIR APPLICATION
CN106103488A (en) Targeting TGF β suppresses
KR20210032311A (en) Heavy chain antibody that binds to CD19
KR20150082316A (en) Novel antigen binding proteins and its use as addressing product for the treatment of cancer
RU2010119450A (en) ANTIBODY AGAINST BST2
MY137078A (en) Recombinant antibodies associated to gangliosides. their use indiagnosis and treatment of tumors.
KR20240038138A (en) Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
CN114269782B (en) anti-TIGIT antibodies and uses thereof
KR20200120648A (en) Anti-PD-1/anti-HER2 natural antibody structure heterodimeric bispecific antibody and its preparation method
US20220064314A1 (en) Cd137 agonist antibodies and uses thereof
KR20200128544A (en) PD1 binder
CA2308007A1 (en) Enhancer for antibody to lymphocytic tumors